10
ALL1
Abbisko Therapeutics6
Arrivent3
InnoCare PharmaYear
10
ALL3
20245
20231
20221
2021DEALS // DEV.
10
ALL6
Deals4
DevelopmentsCountry
10
ALL4
CHINA6
U.S.A10
ALL1
Arrivent2
Goldman Sachs & Co.1
Hillhouse Capital Group4
Inapplicable1
Shanghai Allist Pharmaceuticals1
SofinnovaTherapeutic Area
10
ALL10
OncologyStudy Phase
10
ALL3
Approved FDF3
Phase III2
Phase I1
IND Enabling1
PreclinicalDeal Type
10
ALL1
Collaboration4
Inapplicable1
Licensing Agreement2
Public Offering1
Series A Financing1
Series B FinancingProduct Type
10
ALL10
Other Small MoleculeDosage Form
10
ALL3
Oral6
Oral Tablet1
UndisclosedLead Product
10
ALL1
ABK33769
FurmonertinibTarget
10
ALL1
EGFR3
SHP26
pan-EGFR mutantLead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
InnoCare Doses First Patient In Study Of ICP-189 Combined With Furmonertinib
Details :
Product Name : ICP-189
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2024
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $175.0 million
Deal Type : Public Offering
ArriVent Announces Pricing of Upsized Initial Public Offering
Details : Proceeds will support NDA approval for furmonertinib, a novel oral EGFR kinase inhibitor with broad activity across EGFR mutations.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 25, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $175.0 million
Deal Type : Public Offering
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $135.7 million
Deal Type : Public Offering
Arrivent Unveils $135M IPO Pricing to get Furmonertinib to FDA
Details : The net proceeds will be used for the clinical development of (furmonertinib), which focuses on EGFR mutant-selective tyrosine kinase inhibitors that are developed for NSCLC patients.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co.
Deal Size : $135.7 million
Deal Type : Public Offering
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : ICP-189
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Arrivent
Deal Size : Undisclosed
Deal Type : Collaboration
InnoCare and ArriVent Announce Clinical Development Collaboration
Details :
Product Name : ICP-189
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 13, 2023
Lead Product(s) : ICP-189,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Arrivent
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sofinnova
Deal Size : $155.0 million
Deal Type : Series B Financing
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
Details : The net proceedings will be used to support pivotal Phase 3 and additional studies with the Company’s lead product candidate AST2818 (furmonertinib), a highly brain penetrant, mutant-specific EGFR kinase inhibitor.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sofinnova
Deal Size : $155.0 million
Deal Type : Series B Financing
Lead Product(s) : ABK3376,Furmonertinib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Shanghai Allist Pharmaceuticals
Deal Size : $187.9 million
Deal Type : Licensing Agreement
Shanghai's Abbisko Out-Licenses EGFR Candidate in Potentially Nine-Figure Deal
Details :
Product Name : ABK3376
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 03, 2023
Lead Product(s) : ABK3376,Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Shanghai Allist Pharmaceuticals
Deal Size : $187.9 million
Deal Type : Licensing Agreement
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AST2818 (furmonertinib) is an oral, small molecule, highly brain-penetrant, pan-EGFR mutant inhibitor that targets both classical (exon 19 deletion and L858R) and atypical EGFR mutations, including exon 20 insertion mutations as well as HER2 exon 20 inse...
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing
Details : Allist Pharma received approval for furmonertinib in EGFR T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) indications in China in March 2021.
Product Name : AST2818
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 30, 2021
Lead Product(s) : Furmonertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Hillhouse Capital Group
Deal Size : $150.0 million
Deal Type : Series A Financing